Introduction
The sensitivity of the IgA-class endomysial antibody (EmA) test is 85±100%, and the speci®city close to 100% in untreated coeliac disease [1±4] . However, the test is not as reliable in the assessment of dietary compliance or small bowel mucosal recovery. EmA may be normal even when dietary transgressions are evident [5, 6] . Similarly, negative EmA has been found despite persisting small bowel mucosal atrophy in patients maintaining a gluten-free diet [5±8]. On the other hand, some patients showing normal small bowel mucosal morphology have still remained EmA-positive [2, 9] .
Recently, tissue transglutaminase was recognized as being the major antigen of EmA [10] . An enzymelinked immunosorbent assay (ELISA) test for IgA-class tissue transglutaminase antibodies (tTG-ab) has since been developed, and may be even more sensitive than EmA in detecting coeliac disease [11, 12] . During a gluten-free diet tTG-ab values seem to decrease sig-ni®cantly [11±14], but there are no studies comparing tTG-ab to small bowel mucosal histology during a gluten-free diet. Provided that a negative tTG-ab invariably signi®es adequate morphological recovery, the test could substitute the biopsy in dietary assessment. We tested this hypothesis in a number of adult coeliac patients who had been on a gluten-free diet for variable periods. For comparison, an EmA test was carried out concomitantly.
Patients and methods

Patients
Eighty-seven consecutive adult coeliac disease patients on a gluten-free diet were enrolled for the study (Table 1 ). In all cases the diagnosis was initially based on small bowel mucosal villous atrophy and crypt hyperplasia. Patients with selective IgA de®ciency were not included. A dietician evaluated dietary compliance by means of an interview and a 3 day record of food intake. The glutenfree diet was regarded as strict when no additional gluten intake was shown. Patients were considered to have diet-ary transgressions when admitting every week or at least once a month occasional consumption of gluten-containing foods, such as bread or cake. Histological and serological data were further analysed on 30 (six male, 24 female, median age 46 years, range 22±69 years) of these 87 patients also before the introduction of the diet. This was in order to survey whether the overall decrease of antibodies in serial testing would improve the value of the tests.
Serology
Serum IgA-class tTG-ab was determined by ELISA (Inova Diagnostics, San Diego, California, USA) [11] ; an arbitrary unit value (U) > 20 U for tTG-ab was considered positive. An indirect immuno¯uorescence method was used in the determination of serum IgA-class EmA, using human umbilical cord [15] as antigen. A screening dilution of 1:5 was considered positive, and positive sera were further diluted 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000, 1:4000 and 1:8000. IgA-class gliadin antibody (AGA) was not determined, because its sensitivity and speci®city were expected to be low [6, 11] .
In the present study tTG-ab was investigated by using guinea pig liver tissue transglutaminase as antigen. Recently, a tTG-ab test by human recombinant tissue transglutaminase has been introduced. For comparison, afterwards we tested 105 serum samples outside the original study protocol with Inova's test and with a human recombinant tTG-ab test (Celikey, Pharmacia, Uppsala, Sweden).
Small bowel biopsy
Biopsy specimens were taken from the distal part of the duodenum upon endoscopy. Specimens were stained with haematoxylin±eosin, studied under light microscopy and classi®ed according to Marsh [16, 17] . The lesion was scored as type 0 when there were normal ®nger-like villi with a normal crypt depth and no excess of intraepithelial lymphocytes. In type 1±2 lesions intraepithelial lymphocytosis was seen in normal villous structure without ( Marsh 1) or with ( Marsh 2) hyperplastic crypts. A type 3a lesion comprised partial villous atrophy with crypt hyperplasia, type 3b of subtotal, and 3c of total villous atrophy with crypt hyperplasia. A Marsh 3a±c lesion was considered an inadequate dietary response.
In the follow-up study, comparison was carried out to determine how the overall decline in tTG-ab units on a gluten-free diet was seen as an improvement in small bowel mucosal morphology.
Statistics
Fisher's exact test was used in cross-tabulations. P values lower than 0.05 were considered statistically signi®cant.
Ethics
The protocol of the study was approved by the ethics committee of Tampere University Hospital. All subjects gave informed consent.
Results
tTG-ab were negative in 16 (59%) and EmA in 20 (74%) out of 27 coeliac patients showing persistent small bowel mucosal villous atrophy (Marsh 3a±c) under dietary treatment ( Fig. 1 ) (P 0.12). Thus, the sensitivity of tTG-ab in revealing a severe mucosal lesion was only 41% ( Table 2 ). The majority of patients showing Marsh 1±2 type lesions were antibody negative.
In the follow-up study, tTG-ab values declined within 1 year of gluten-free treatment in all 30 patients (Fig.  2) . tTG-ab were consistently within reference values when adequate mucosal recovery was obtained ( Fig. 2A  and B ). However, ®ve patients showed a Marsh 3 lesion despite normal antibody levels, and notably, the overall decrease in tTG-ab units had been substantial in most of them (Fig. 2C ).
In the dietary assessment, 76 (87%) out of 87 coeliac disease patients adhered to a strict gluten-free diet. Eleven patients were found to have occasional dietary transgressions, such as consumption of gluten-containing bread weekly or at least once a month; both serum tTG-ab and EmA were negative in six of them ( Fig. 1A 
Discussion
In coeliac disease, the assessment of dietary response has been based on morphological recovery of small bowel mucosa during follow-up. A serological test able to substitute biopsy ought to reveal effectively such patients who still have ongoing mucosal damage, especially a Marsh 3 lesion. False-positive test results would not be as problematic as negative ones, since positive cases can well be veri®ed by biopsy. We showed for the ®rst time that in many cases, seroconversion of tTG-ab during a gluten-free diet does not necessarily ally with morphological recovery. Even a signi®cant decrease in absolute units can occur in the absence of unequivocal mucosal improvement (Fig. 2C) . Thus, the test cannot replace small bowel biopsy in interpreting the adequacy of a gluten-free diet. In fact, tTG-ab was not de®nitely superior to EmA in this respect.
Dickey and associates [8] suggested that even though EmA does not disappear concomitantly with mucosal recovery, the test may be of value in monitoring dietary compliance; four out of their ®ve patients with dietary lapses were EmA positive. By contrast, in the present study most (55%) coeliac patients found to have repeated, albeit occasional, dietary transgressions remained both tTG-ab-and EmA negative. This indicates that the normalization of antibodies does not always indicate adequate dietary compliance. Figure 1 shows, however, that occasional dietary lapses strongly indicate the presence of villous atrophy: a Marsh 3 lesion was present in ®ve out of nine such cases.
On the other hand, when serum tTG-ab or EmA remained positive after one year on a gluten-free diet, there was consistently ongoing disease activity in the small bowel mucosa (Fig. 2) . In other words, positive values seem to indicate inadequate mucosal response. Therefore, provided that the limitations of negative test results are recognized, the antibody tests are bene®cial in respect of timing biopsy. It can further be seen in Figure 2 that even on a strict gluten-free diet complete mucosal recovery may sometimes take 1 year or even longer, as also previously noted [18] .
The antibody assays seemed to work no better in longterm treated patients than in the whole group: in patients adopting gluten-free diet for more than 5 years (n 28), four had Marsh 3 small bowel mucosal villous atrophy, and two of them were both tTG-ab and EmA negative. Furthermore, nine out of 28 had dietary transgressions, but only four were positive for these antibodies.
IgA-class AGA has been reliable in detecting small bowel villous atrophy, but the low sensitivity of the test has been problematic [19] . Moreover, AGA has been poor in predicting villous atrophy in treated coeliac disease patients [6] . Therefore, we did not use IgAclass AGA in the follow-up of dietary treatment.
Our tTG-ab test was based on guinea pig liver tissue transglutaminase as antigen. It seems unlikely that the latest tTG-ab tests based on a human recombinant technique would be signi®cantly superior for detecting poor small bowel mucosal recovery. As expected, the test we used showed somewhat more marginally positive ®ndings. However, as earlier stated, a positive result can be veri®ed by intestinal biopsy. It is of note that our test was in no case negative when human recombinant test was positive.
To conclude, we consider that tTG-ab (or EmA) has some use in evaluating the adequacy of a gluten-free diet. However, the test is not sensitive enough to reveal dietary transgressions or poor small bowel mucosal recovery in coeliac disease, and hence cannot substitute the control biopsy.
